Hormonal IUD (Mirena/Kyleena) for Women 65 and Older: Caregiver Administration Guidance

Why an Older Woman Might Still Have a Hormonal IUD

Many women have a levonorgestrel IUD in place long before they turn 65, and the device may still be present if its lifespan has not expired. This matters for caregivers because a woman with cognitive decline, limited mobility, or communication barriers may not be able to report IUD-related symptoms herself.

A hormonal IUD in a postmenopausal woman serves one of two purposes. Either it was placed for contraception during the perimenopausal years and has simply not yet been removed, or it is being used deliberately as the progestogenic component of a hormone replacement regimen. The Menopause Society (formerly NAMS) clinical practice statement on menopausal hormone therapy notes that a levonorgestrel IUD can provide local endometrial protection when systemic estrogen is prescribed, allowing women who prefer transdermal or vaginal estrogen to avoid systemic oral progestins.

What the Numbers Look Like

The FDA-approved duration for the 52 mg Mirena IUD was extended to 8 years in 2022. Kyleena (19.5 mg) carries a 5-year FDA-approved lifespan. A woman who had Mirena placed at age 58 could still have an active device at 65. One placed at age 60 could theoretically still be in place and within label at 68.

Roughly 10-15% of perimenopausal women using systemic estrogen therapy opt for a levonorgestrel IUD as their progestogen source, so this is not a rare clinical scenario for caregivers.

The Non-Contraceptive Reason It Stays In

After menopause, the ovaries stop releasing eggs. A woman who is clearly postmenopausal has no biological need for contraception. If the IUD is still in place past her last menstrual period and confirmed menopause, it is there for endometrial protection during estrogen therapy, for management of any residual bleeding disorder, or simply because removal has not been scheduled. The caregiver's job is not to decide whether it stays or goes. That decision belongs to the prescribing clinician. The caregiver's job is to monitor, communicate, and ensure the woman gets the clinical review she needs on schedule.

What Levonorgestrel Does Inside an Older Woman's Body

The levonorgestrel released locally from a Mirena IUD is absorbed systemically, but at low levels. Serum levonorgestrel concentrations from the 52 mg IUD average approximately 150-200 pg/mL after the first year, declining over time. These concentrations are substantially lower than those from oral contraceptives or the hormonal implant.

In a postmenopausal woman, there is no endogenous estrogen or progesterone to interact with. The local progestogenic effect on the endometrium is the primary action. The endometrium remains thin and atrophic, which is the intended outcome when the device is being used alongside systemic estrogen.

Does Metabolism Change at 65+?

Yes, and this is clinically meaningful. Hepatic enzyme activity changes with age. Body fat percentage increases and lean mass falls, altering the distribution of lipophilic hormones. A pharmacokinetic analysis published in Contraception found that older age was associated with modestly lower levonorgestrel clearance, meaning serum levels may run slightly higher in a 68-year-old than in a 35-year-old with the same device. This is unlikely to cause harm at the low concentrations involved, but it is a reason to discuss the continued need for the device at every annual clinical visit.

Bone Health Consideration

Postmenopausal bone loss is a major concern for women in this age group. The ACOG Committee Opinion on osteoporosis in women notes that low-dose progestogen exposure from an IUD does not negatively affect bone mineral density and that estrogen-containing HRT has positive skeletal effects. If the woman is using the IUD alongside systemic estrogen for HRT, she may actually be protecting bone as well as endometrium. This is a clinical benefit caregivers should be aware of when reviewing the overall medication picture.

How Long Can the IUD Stay In? Device Lifespan at a Glance

The lifespan limits are hard cutoffs set by the FDA based on hormonal reservoir depletion data, not on a woman's age.

| Device | Approved duration | Hormone dose | |---|---|---| | Mirena (52 mg LNG) | 8 years | ~20 mcg/day initial, declining | | Kyleena (19.5 mg LNG) | 5 years | ~17.5 mcg/day initial, declining | | Liletta (52 mg LNG) | 8 years | ~18.6 mcg/day initial, declining |

ACOG Practice Bulletin No. 186 on long-acting reversible contraception recommends device removal and replacement at the FDA-approved interval if continued use is clinically intended. An expired IUD sitting in the uterus of a woman who is not being monitored is a foreign body with uncertain hormone delivery and potential infection risk. Caregivers should know the insertion date and mark the expiration date on a shared health calendar.

When the Device Must Come Out Before Expiration

Removal before the labeled lifespan is required in several situations:

• The woman or her healthcare proxy requests removal
• Uterine infection (endometritis, pelvic inflammatory disease) is confirmed
• The device has partially or fully expelled
• The woman develops unexplained uterine bleeding that warrants investigation without the device in place
• Uterine or cervical malignancy is diagnosed
• The woman's systemic estrogen therapy is discontinued and the IUD is no longer serving a therapeutic purpose

The clinician makes the removal decision. The caregiver's role is to flag the symptoms that trigger that conversation.

Caregiver Administration Guidance: What This Actually Means Day to Day

Caregivers do not insert or remove IUDs. That is performed by a trained clinician in a clinical setting. Caregiver administration guidance for an IUD refers to ongoing monitoring, symptom recognition, communication with the healthcare team, and supporting the woman through any required procedures.

Checking the Strings

A gynecologist or NP will periodically check that the IUD strings are palpable at the cervix during a pelvic exam. For women who are cognitively intact and mobile, this happens at annual well-woman visits. For women who are cognitively impaired, bedbound, or in long-term care, the caregiver must ensure that scheduled clinical visits actually happen and that the clinical team is aware the device is in place.

If the woman reports that she can no longer feel the strings herself (applicable only to women who have historically done self-checks), or if she reports pelvic pressure, pain, or any change in her body, this should be communicated to the clinical team promptly.

Recognizing Complications in a Woman Who May Not Self-Report

The following framework is designed specifically for caregivers supporting older women with cognitive impairment or communication barriers. Standard IUD complication checklists assume the patient can self-report. This adaptation addresses what a caregiver can observe externally.

Possible expulsion: Visible device or strings outside the vaginal opening. Unexplained discomfort when seated. Report to the clinical team within 24 hours. Do not attempt to reinsert or manipulate the device.

Possible perforation: Though rare (estimated at approximately 1 in 1,000 insertions), perforation can occur. In an older woman with an existing device, late migration is uncommon but documented. Signs may include new pelvic pain, inability to locate strings at a routine exam, or incidental finding on imaging. This requires urgent clinical evaluation.

Possible infection: Fever, foul-smelling vaginal discharge, lower abdominal tenderness that the woman expresses through guarding or behavioral change (agitation, refusing care), or warmth and redness visible at the vulva. The baseline PID risk with IUDs is low after the first 20 days post-insertion, but risk increases if the woman is immunocompromised, has diabetes, or has had recent instrumentation.

Unexplained vaginal bleeding: Any vaginal bleeding in a confirmed postmenopausal woman requires clinical evaluation regardless of the IUD. ACOG Committee Opinion 734 states that postmenopausal bleeding warrants evaluation to exclude endometrial pathology in all cases. The IUD does not make bleeding normal after menopause.

Supporting the Removal Procedure

Removal of an IUD from a postmenopausal woman can be more uncomfortable than removal from a premenopausal woman because cervical stenosis is common after estrogen withdrawal. Cervical stenosis affects a significant proportion of postmenopausal women and can make IUD string retrieval and removal technically challenging.

Caregivers supporting a woman through an IUD removal appointment should:

• Confirm the woman's healthcare proxy status if she lacks decision-making capacity
• Bring the original insertion records if available, including the device lot number and insertion date
• Ask the clinical team about pre-procedure misoprostol or topical anesthetic options, which may ease cervical dilation in postmenopausal patients
• Arrange transport that allows for rest after the procedure, as cramping and light spotting are common for several hours

Pregnancy and Lactation Safety

Pregnancy at 65+ is biologically impossible in a naturally postmenopausal woman. This section is included because it is required for all drug-related articles on this platform, and because caregivers sometimes support women who were in the perimenopausal transition when the device was placed.

A woman who has not had a period for 12 consecutive months is considered postmenopausal by the standard clinical definition used by The Menopause Society. At that point, spontaneous pregnancy is not possible.

During the perimenopausal years leading up to that final period, ovulation can still occur intermittently. The levonorgestrel IUD is highly effective at preventing pregnancy during this window, with a failure rate of less than 0.1-0.2% per year for the 52 mg device in reproductive-age women. No specific failure rate data exists for women in their early to mid-60s who have not yet confirmed menopause, because this group has been largely excluded from IUD trials. That is an evidence gap caregivers and clinicians should acknowledge.

Levonorgestrel IUD in pregnancy: If a woman becomes pregnant with an IUD in place at any age, the device should be removed as early as possible. Retained IUD in pregnancy is associated with increased risk of miscarriage, preterm birth, and infection. The FDA prescribing information for Mirena states that if pregnancy occurs with the IUD in situ, the device should be removed if the strings are visible.

Lactation: Not applicable for women aged 65+. Levonorgestrel IUDs are considered compatible with breastfeeding in younger postpartum women, but this is not a clinical scenario in geriatric care.

Contraception counseling for the 60-64 year old in perimenopause: A woman aged 60-64 who has not yet confirmed menopause still technically requires contraception if she is sexually active with a partner who produces sperm. The levonorgestrel IUD remains an appropriate option in this group. ACOG and the CDC U.S. Medical Eligibility Criteria for Contraceptive Use list the levonorgestrel IUD as Category 1 (no restriction) for women aged 45 and older, including those in perimenopause.

Who This Device Is Right For (and Who Should Have It Removed)

Women for Whom Continuing the IUD Makes Sense

An older woman is a reasonable candidate for keeping a hormonal IUD in place if:

• She is receiving systemic estrogen therapy for menopausal symptoms and needs endometrial protection
• The device is within its FDA-approved lifespan
• She has had no complications and clinical exams confirm correct placement
• She or her healthcare proxy understands the device is in place and what monitoring is required
• She has a history of endometrial hyperplasia for which ongoing progestogenic protection is clinically indicated

Women for Whom Removal Is the Better Choice

Removal is the more appropriate path if:

• The device has expired (past 8 years for Mirena, past 5 years for Kyleena)
• The woman has discontinued all systemic estrogen and has no other indication for the device
• She has developed uterine or cervical pathology requiring clear visualization or treatment
• She is cognitively impaired, her whereabouts are unknown to her care team, and there is no record of the device or its placement date (a clinical work-up including pelvic ultrasound is needed to locate the device)
• Her healthcare proxy or the clinical team cannot confirm continued clinical benefit

The Society of Family Planning recommends that IUDs in postmenopausal women without an ongoing indication be removed at the next convenient opportunity, as they offer no benefit and carry a small ongoing risk as a foreign body.

Cognitive Impairment and Consent: A Caregiver's Specific Responsibility

A woman with moderate to severe dementia may not be able to communicate pain, discomfort, or symptoms that indicate a complication. She also may not be able to provide or withdraw consent for procedures.

Medical decision-making capacity is distinct from legal competency and is assessed by the treating clinician for each specific decision. A woman may lack capacity to decide about IUD management even if she retains capacity in other areas of daily life.

Caregivers in this situation should:

• Identify the healthcare proxy or power of attorney for health care decisions
• Ensure the proxy is actively involved in all gynecologic care decisions
• Request a clinical ethics consult at the treating facility if there is uncertainty about whether removal or continuation is in the woman's best interest
• Document all communications with the clinical team

The American College of Obstetricians and Gynecologists' Committee Opinion on Ethical Decision-Making in Obstetrics and Gynecology states that surrogate decision-makers should apply a substituted judgment standard, choosing what the patient would have wanted, or a best-interest standard when her prior wishes are unknown.

For women in long-term care facilities, ensure the admissions and nursing staff have the IUD documented in the medication administration record. It is a medical device, and its presence should be treated with the same documentation rigor as a pacemaker or a prosthetic joint.

Drug Interactions and Concurrent Medications Common at 65+

Older women are typically on multiple medications. A few interactions are worth noting for the levonorgestrel IUD specifically.

CYP3A4 inducers: Drugs that induce hepatic CYP3A4 (including rifampin, certain anticonvulsants such as carbamazepine and phenytoin, and St. John's Wort) may increase levonorgestrel metabolism and reduce serum levels. Because the IUD's primary action is local rather than systemic, the clinical significance of this interaction is thought to be lower than with oral levonorgestrel, but data in older women specifically is limited. If a woman on a strong CYP3A4 inducer is relying on her IUD for endometrial protection alongside estrogen, her clinician should confirm that endometrial suppression remains adequate.

Anticoagulants: Many women aged 65+ take warfarin, apixaban, or rivaroxaban. The levonorgestrel IUD has a favorable profile here because it reduces or eliminates uterine bleeding, which lowers the bleeding risk associated with anticoagulation. A Cochrane review on contraception in women with cardiovascular conditions supports the use of levonorgestrel IUDs in anticoagulated women.

Corticosteroids: Long-term corticosteroid use, common in older women with autoimmune conditions or chronic lung disease, is associated with reduced immune function. This may slightly raise infection risk with any intrauterine device, though the absolute risk remains low.

Immunosuppressants: Women on immunosuppressants post-transplant warrant extra vigilance for infection symptoms. Report any fever or pelvic discomfort promptly.

Monitoring Schedule the Caregiver Should Track

| Time point | What should happen | |---|---| | Every 12 months | Well-woman visit with pelvic exam; strings confirmed; continued indication reviewed | | At device expiration | Removal and decision about replacement | | Any new symptom | Contact clinical team; do not wait for scheduled visit | | Change in HRT regimen | Discuss with prescriber whether IUD indication still applies | | Change in cognitive status | Reassess consent capacity and ensure proxy is engaged |

A woman aged 65 or older should not be going more than 12 months without a provider physically confirming the IUD is in place, especially if she cannot report symptoms herself. If her last documented pelvic exam is older than 12 months, schedule one now.